RxDoctor Payments Data

James Coleman

Family Medicine · Opelika, ALNPI 1699061291

Payments from drug & device makers

$899in general payments, 2019–2025

Across 53 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$168
  • AstraZeneca$135
  • GSK$121
  • Boehringer Ingelheim$100
  • Lilly USA, LLC$77
  • Novo Nordisk$42
  • plus $255 from 11 others

What the payments were for

  • Food & beverage$899100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$899 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$141,908
Medicare patients
347
Services billed
1,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$174,218
JardianceEmpagliflozin154$170,433
EliquisApixaban91$91,096
MounjaroTirzepatide66$68,076
FarxigaDapagliflozin Propanediol36$37,611
RybelsusSemaglutide18$32,950
XareltoRivaroxaban19$23,189
JanuviaSitagliptin Phosphate15$17,480
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,242
Tresiba Flextouch U-200Insulin Degludec17$15,061
LinzessLinaclotide17$14,333
Amlodipine-ValsartanAmlodipine Besylate/Valsartan210$11,489
Tresiba Flextouch U-100Insulin Degludec16$11,152
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide260$11,016
Rosuvastatin Calcium529$7,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$42$207,168167 claims
Boehringer IngelheimJardiance$100$170,433154 claims
PfizerEliquis, Paxlovid$28$92,464107 claims
Lilly USA, LLCMounjaro$77$68,07666 claims
AstraZenecaFarxiga$135$37,61136 claims
GSKTrelegy Ellipta, Breo Ellipta$121$19,45633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →